Population-based analysis of curative therapies in stage II non-small cell lung cancer: the role of radiotherapy in medically inoperable patients

by Sara Moore, Bonnie Leung, Jonn Wu, Cheryl Ho
Published 2020-01-01

FDA Accelerated Approval for Malignant Hematology and Oncology Indications in the Canadian Environment

by Cheryl Ho, Howard J. Lim, Dean A. Regier
Published 2022-01-01

A retrospective review of the multidisciplinary management of medullary thyroid cancer: eligibility for systemic therapy

by Georgia Geller, Janessa Laskin, Winson Y. Cheung, Cheryl Ho
Published 2017-09-01

Real-world eligibility for platinum doublet plus immune checkpoint inhibitors in extensive-stage small-cell lung cancer

by Rebekah Rittberg, Bonnie Leung, Zamzam Al-Hashami, Cheryl Ho
Published 2022-09-01

Real World Patient Eligibility for Second Line Lurbinectedin Based Treatment in Small Cell Lung Cancer: Understanding Epidemiology and Estimating Health Care Utilization

by Rebekah Rittberg, Bonnie Leung, Zamzam Al-Hashami, Cheryl Ho
Published 2022-12-01

Predicting which patients with cancer will see a psychiatrist or counsellor from their initial oncology consultation document using natural language processing

by John-Jose Nunez, Bonnie Leung, Cheryl Ho, Raymond T. Ng, Alan T. Bates
Published 2024-04-01

Psychosocial Distress Scores and Needs among Newly Diagnosed Sarcoma Patients: A Provincial Experience

by Amirrtha Srikanthan, Bonnie Leung, Aria Shokoohi, Alannah Smrke, Alan Bates, Cheryl Ho
Published 2019-01-01

Real world duration of curative intent breast, colorectal, non-small cell lung, and prostate cancer treatment

by Selina K. Wong, Jeremy Hamm, Aria Shokoohi, Colleen E. McGahan, Cheryl Ho
Published 2021-03-01

Survival Outcomes of Salvage Therapy for Local and Regionally Recurrent NSCLC

by Sara Moore, MD, FRCPC, Bonnie Leung, NP, Jonn Wu, MD, FRCPC, Cheryl Ho, MD, FRCPC
Published 2020-11-01

Real-World Clinical Outcomes for Patients with <i>EGFR</i> and <i>HER2</i> Exon 20 Insertion-Mutated Non-Small-Cell Lung Cancer

by Kelly Li, Ian Bosdet, Stephen Yip, Cheryl Ho, Janessa Laskin, Barbara Melosky, Ying Wang, Sophie Sun
Published 2023-07-01

Real-World Outcomes of Stage IV NSCLC with PD-L1 ≥ 50% Treated with First-Line Pembrolizumab: Uptake of Second-Line Systemic Therapy

by Rebekah Rittberg, Bonnie Leung, Aria Shokoohi, Alexandra Pender, Selina Wong, Zamzam Al-Hashami, Ying Wang, Cheryl Ho
Published 2023-05-01

Discordance in PD-L1 scores on repeat testing of non-small cell lung carcinomas

by Julia R. Naso, Norbert Banyi, Zamzam Al-Hashami, Jingyao Zhu, Gang Wang, Diana N. Ionescu, Cheryl Ho
Published 2021-01-01

Applicability of the PACIFIC trial results in patients not eligible for the PACIFIC trial: Canadian rapid consensus statement and recommendations.

by Dr.Andrew G. Robinson, Stephanie Snow, Anthony Brade, Cheryl Ho, Paul Wheatley-Price, Normand Blais, Parneet Cheema, Anand Swaminath
Published 2020-01-01

Alternate Pembrolizumab Dosing Interval in Advanced NSCLC with PD-L1 TPS ≥ 50%: 3 Weekly Compared to 6 Weekly Dosing

by Lauren Jones, Rebekah Rittberg, Bonnie Leung, Aria Shokoohi, Alexandra Pender, Selina Wong, Zamzam Al-Hashami, Ying Wang, Cheryl Ho
Published 2022-11-01

Disparate Time-to-Treatment and Varied Incidence of Actionable Non-Small Cell Lung Cancer Molecular Alterations in British Columbia: A Historical Cohort Study

by Roy Avraham Hilzenrat, Stephen Yip, Barbara Melosky, Cheryl Ho, Janessa Laskin, Sophie Sun, James J. Choi, Anna L. McGuire
Published 2022-12-01

Effect of targeted therapy and immunotherapy on advanced nonsmall‐cell lung cancer outcomes in the real world

by Aria Shokoohi, Zamzam Al‐Hashami, Sara Moore, Alexandra Pender, Selina K. Wong, Ying Wang, Bonnie Leung, Jonn Wu, Cheryl Ho
Published 2022-01-01

Improved uptake and survival with systemic treatments for metastatic non-small cell lung cancer: younger versus older adults

by Bonnie Leung, Aria Shokoohi, Zamzam Al-Hashami, Sara Moore, Alexandra Pender, Selina K. Wong, Ying Wang, Jonn Wu, Cheryl Ho
Published 2023-04-01

A perspective on life-cycle health technology assessment and real-world evidence for precision oncology in Canada

by Dean A. Regier, Samantha Pollard, Melanie McPhail, Tania Bubela, Timothy P. Hanna, Cheryl Ho, Howard J. Lim, Kelvin Chan, Stuart J. Peacock, Deirdre Weymann
Published 2022-10-01

Beyond PACIFIC: Real-World Outcomes of Adjuvant Durvalumab According to Treatment Received and PD-L1 Expression

by Marie-Hélène Denault, Jamie Feng, Shelley Kuang, Aria Shokoohi, Bonnie Leung, Mitchell Liu, Eric Berthelet, Janessa Laskin, Sophie Sun, Tina Zhang, Cheryl Ho, Barbara Melosky
Published 2023-08-01

Prediction of Disease Progression to Upfront Pembrolizumab Monotherapy in Advanced Non-Small-Cell Lung Cancer with High PD-L1 Expression Using Baseline CT Disease Quantification an...

by Ali Silver, Cheryl Ho, Qian Ye, Jianjun Zhang, Ian Janzen, Jessica Li, Montgomery Martin, Lang Wu, Ying Wang, Stephen Lam, Calum MacAulay, Barbara Melosky, Ren Yuan
Published 2023-06-01